🎉 M&A multiples are live!
Check it out!

Allakos Valuation Multiples

Discover revenue and EBITDA valuation multiples for Allakos and similar public comparables like Pharming, Galapagos, and Vivoryon Therapeutics.

Allakos Overview

About Allakos

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.


Founded

2012

HQ

United States of America
Employees

61

Website

allakos.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$47.7M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Allakos Financials

Allakos has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Allakos achieved revenue of n/a and an EBITDA of -$111M.

Allakos expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Allakos valuation multiples based on analyst estimates

Allakos P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$190M -$111M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$320M -$186M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Allakos Stock Performance

As of April 15, 2025, Allakos's stock price is $0.

Allakos has current market cap of $29.0M, and EV of -$47.7M.

See Allakos trading valuation data

Allakos Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$47.7M $29.0M XXX XXX XXX XXX $-1.10

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Allakos Valuation Multiples

As of April 15, 2025, Allakos has market cap of $29.0M and EV of -$47.7M.

Allakos's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Allakos's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Allakos and 10K+ public comps

Allakos Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$47.7M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.4x XXX XXX XXX
P/E -0.3x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Allakos Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Allakos Valuation Multiples

Allakos's NTM/LTM revenue growth is n/a

Allakos's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.9M for the same period.

Over next 12 months, Allakos's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Allakos's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Allakos and other 10K+ public comps

Allakos Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -42% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Allakos Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Allakos M&A and Investment Activity

Allakos acquired  XXX companies to date.

Last acquisition by Allakos was  XXXXXXXX, XXXXX XXXXX XXXXXX . Allakos acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Allakos

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Allakos

When was Allakos founded? Allakos was founded in 2012.
Where is Allakos headquartered? Allakos is headquartered in United States of America.
How many employees does Allakos have? As of today, Allakos has 61 employees.
Who is the CEO of Allakos? Allakos's CEO is Dr. Robert Alexander, PhD.
Is Allakos publicy listed? Yes, Allakos is a public company listed on NAS.
What is the stock symbol of Allakos? Allakos trades under ALLK ticker.
When did Allakos go public? Allakos went public in 2018.
Who are competitors of Allakos? Similar companies to Allakos include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Allakos? Allakos's current market cap is $29.0M
Is Allakos profitable? Yes, Allakos is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.